Snowdon Inc. is a pharmaceutical company focused on three major therapeutic areas with substantial market potential: acute and chronic pain, neurological disorders, and infectious diseases. These medical conditions cause immense suffering, economic hardship, and loss of life among millions of people every day. The companyâs projects include a preclinical compound SND-121 for the treatment for neuropathic pain; SND-159 for tuberculosis; and SND-226 for toxoplasmosis. The firm was also pursuing early stage discovery projects aimed at novel medical treatments for neurological disorders, such as Fragile X Syndrome, which is the most common known cause of autism and autistic-like behaviors. Snowdon Pharmaceuticals Inc. had been providing computational tools rapidly to identify high-value molecules from their library of vendor-available compounds. Website still functional but no added content post c. 200
